Important Patient Notice: A recent data security incident affected patients receiving services from Onco360. This notice provides information to all potentially affected individuals about the incident.
Onco360 announces selection to highly limited pharmacy network for NERLYNX.
Onco360 is a Silver Sponsor at this years Asembia Specialty Pharmacy Summit; Also Featured During Two Panel Sessions
Onco360 announces selection to highly limited pharmacy network for VENCLEXTA.
Limited distribution medication XALKORI (crizotinib) receives approval for certain NSCLC patients.
Limited distribution breast cancer medication IBRANCE approved for additional indication.
Imatinib Mesylate (generic Gleevec) was recently approved for 7 indications.
Combination therapy receives accelerated approval for new indication. OPDIVO also receives additional indication as a single therapy.
Onco360 Selected for Lonsurf Limited Distribution Pharmacy Network
Onco360 will be exhibiting at NASP's Annual Meeting
Onco360 Receives URAC Specialty Pharmacy Accreditation...
Newly Approved Ibrance® (palbociclib) From Pfizer Available Through Onco360; Company Again Selected as Limited Distribution Pharmacy Provider
Onco360 Chosen By Bayer As Limited Distribution Pharmacy Provider
Company’s Comprehensive Drug Portfolio Further Expands with Addition of Two Leading Products
Onco360 Selected by Pfizer as Limited Distribution Pharmacy Provider;
Expands Onco360’s Industry-Leading Portfolio to Nearly 40 Products
Onco360 Appoints Paul Jardina as President and Chief Executive Officer
Jardina Brings More Than 20 Years of Healthcare Industry Experience
Zydelig® (idelalisib) approved and available for order through Onco360
IMBRUVICA is now also indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL), who have received at least one prior therapy.